AlphAIAlphAI — Financial news for AI agents
tradingview.com$MCK

McKesson 2Q 2026: Revenue $110.96B, Net income $1.22B, EPS $10.44— 10-Q Summary

McKesson reported 2Q 2026 revenue of $110.96B, up 7.6% YoY, with net income of $1.22B (up 9.7%) and EPS of $10.44 (up 17%). Growth was driven by North American Pharmaceutical, Oncology & Multispecialty, and Prescription Technology Solutions. The company plans to separate its Medical-Surgical Solutions division, which saw a 5% revenue increase.

Original reporting
tradingview.com
Published Nov 4, 2026, 10:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 10:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
McKesson 2Q 2026: Revenue $110.96B, Net income $1.22B, EPS $10.44— 10-Q Summary — source image
Source · tradingview.com
Decision brief

The 30-second read

$MCKBullishHigh
01

Why it matters

The earnings beat reinforces the company's growth trajectory and may lift sector sentiment.

02

Market read

Strong earnings from a $110B‑revenue company provide a clear catalyst for traders.

03

What to watch

Potential integration costs from recent acquisitions may temper long‑term upside.

Relevance 8/10Novelty 9/10Timing: after‑hours release

Background

McKesson is a leading U.S. pharmaceutical distributor and health‑care services company.

Company-level read

Ticker impact

$MCKBullishHigh confidence
Context

McKesson reported Q2 2026 results with revenue $110.96B, net income $1.22B and EPS $10.44, all up YoY.

Expected impact

likely upward as market prices in the earnings beat and higher guidance

Evidence & confidence

Revenue and EPS both rose double‑digit percentages, indicating robust performance and potential upside.

Market effects

Sector

Healthcare distribution sector may see broader optimism from McKesson's strong results.

Regional

U.S. pharma wholesale market could experience short‑term buying pressure.

Global

Large U.S. distributor earnings can influence global supply‑chain sentiment.

Counterpoint

What could challenge this read

If the market has already priced in the beat, the stock could face a short‑term pullback.

Key entities

  • Company
    McKesson Corporation

    U.S. healthcare services and pharmaceutical distribution firm.

Read at source← All news

StoryMcKesson posts strong Q2 FY2027 results, raises FY2027 EPS guidance and completes Precision Medicine Group acquisition

Also covered by

5 outlets

Related articles

$MCKHighAI 8/10

McKesson (MCK) Q2 2027 Earnings Call Transcript

McKesson (MCK) reported Q2 2027 earnings, highlighting investments in employee programs and strategic acquisitions. The company acquired Precision Medicine Group to advance its oncology and biopharma services, and plans to invest in Option Care Health. McKesson also extended its distribution agreement with CVS Health. The company reported strong market trends and growth across its platforms, with a focus on technology and automation to enhance services.

finance.yahoo.com
$MCKHighAI 9/10

Key facts: FY27 Outlook Raised; Deals Expanded; PMG Buy, Segment Split

McKesson (MCK) reported Q2 revenue of $110.96B (+8% YoY) and adjusted EPS of $11.68, beating estimates. It raised fiscal 2027 adjusted EPS guidance to $45.60–$46.40. The company extended a drug distribution deal with CVS Health and plans to buy 49% of Option Care Health for $1.4B. McKesson also completed its acquisition of Precision Medicine Group and announced plans to separate its medical-surgical solutions segment.

tradingview.com
$MCKHighAI 9/10

McKesson Corp (MCK) (Q2 2027) Earnings Call Highlights: Raised Guidance, GLP-1 Momentum

McKesson Corp (MCK) raised fiscal 2027 adjusted EPS guidance to $45.60-$46.40, citing 8% revenue growth to $111 billion in Q2. The company acquired Precision Medicine Group for $2.25 billion, extending oncology capabilities. Challenges include lower branded pharmaceutical pricing and medical-surgical segment profit decline. Management discussed strategic investments and long-term growth targets.

finance.yahoo.com
$MCKMedAI 8/10

McKesson Q2 Revenue Rises to $110.96B, EPS $10.44; $221M Restructuring Charge

McKesson reported fiscal Q2 2027 revenue of $110.96B, up from $103.15B a year earlier, with net income of $1.22B and EPS of $10.44. The company recorded $221M in restructuring charges for the six-month period. Gross profit rose to $3.96B, while operating income increased to $1.60B. Share buybacks reduced the weighted-average diluted shares, supporting per-share results. The company faces risks related to opiate litigation and rising interest expenses.

minichart.com.sg
$MCKHighAI 8/10

[McKesson Q2 2027 Earnings Call] McKesson Raises FY2027 EPS Guidance to $45.60-$46.40, Beats on 8% Revenue Growth and 26% GLP-1 Surge

McKesson (MCK) raised its FY2027 EPS guidance to $45.60-$46.40, up from $44.20-$45.00, citing 8% revenue growth and a 26% surge in GLP-1 medication sales. Q2 revenue was $111.0B, up 8%, with adjusted EPS at $11.68, up 18%. The company completed a $2.25B acquisition and plans a $1.4B investment. Management expects 6-10% revenue growth and 12-16% operating profit growth for FY2027.

finance.biggo.com